Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bio-Techne is a biotechnology business based in the US. Bio-Techne shares (TECH) are listed on the NASDAQ and all prices are listed in US Dollars. Bio-Techne employs 3,000 staff and has a trailing 12-month revenue of around $1.1 billion.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $79.83 |
|---|---|
| 52-week range | $67.68 - $113.06 |
| 50-day moving average | $83.24 |
| 200-day moving average | $85.74 |
| Wall St. target price | $104.89 |
| PE ratio | 44.5978 |
| Dividend yield | $0.32 (0.4%) |
| Earnings per share (TTM) | $1.79 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $79.83 from 2023-01-25
| 1 week (2023-01-20) | -2.00% |
|---|---|
| 1 month (2022-12-27) | -2.90% |
| 3 months (2022-10-27) | -73.01% |
| 6 months (2022-07-27) | -78.68% |
| 1 year (2022-01-27) | -77.44% |
|---|---|
| 2 years (2021-01-27) | -74.93% |
| 3 years (2020-01-27) | 216.79 |
| 5 years (2018-01-26) | 142.32 |
Valuing Bio-Techne stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bio-Techne's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bio-Techne's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Bio-Techne shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bio-Techne's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1476. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bio-Techne's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bio-Techne's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $358.5 million.
The EBITDA is a measure of a Bio-Techne's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.1 billion |
|---|---|
| Operating margin TTM | 26.5% |
| Gross profit TTM | $758.1 million |
| Return on assets TTM | 8.01% |
| Return on equity TTM | 16.71% |
| Profit margin | 26.13% |
| Book value | $11.16 |
| Market capitalisation | $12.5 billion |
TTM: trailing 12 months
Dividend payout ratio: 28.43% of net profits
Recently Bio-Techne has paid out, on average, around 28.43% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.4% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bio-Techne shareholders could enjoy a 0.4% return on their shares, in the form of dividend payments. In Bio-Techne's case, that would currently equate to about $0.32 per share.
While Bio-Techne's payout ratio might seem fairly standard, it's worth remembering that Bio-Techne may be investing much of the rest of its net profits in future growth.
Bio-Techne's most recent dividend payout was on 27 November 2022. The latest dividend was paid out to all shareholders who bought their shares by 9 November 2022 (the "ex-dividend date").
Bio-Techne's shares were split on a 4:1 basis on 29 November 2022. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Bio-Techne shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Bio-Techne shares which in turn could have impacted Bio-Techne's share price.
Over the last 12 months, Bio-Techne's shares have ranged in value from as little as $67.675 up to $113.0563. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bio-Techne's is 1.2515. This would suggest that Bio-Techne's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
